227 related articles for article (PubMed ID: 37452107)
1. Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study.
Li L; Wu PS; Liang XM; Chen K; Zhang GL; Su QB; Huo RR; Xie RW; Huang S; Ma L; Zhong JH
J Gastroenterol; 2023 Oct; 58(10):1043-1054. PubMed ID: 37452107
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant immunotherapy improves recurrence-free and overall survival following surgical resection for intermediate/advanced hepatocellular carcinoma
Xu X; Wang MD; Xu JH; Fan ZQ; Diao YK; Chen Z; Jia HD; Liu FB; Zeng YY; Wang XM; Wu H; Qiu W; Li C; Pawlik TM; Lau WY; Shen F; Lv GY; Yang T
Front Immunol; 2023; 14():1322233. PubMed ID: 38268916
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data.
Yoon JS; Song BG; Lee JH; Lee HY; Kim SW; Chang Y; Lee YB; Cho EJ; Yu SJ; Sinn DH; Kim YJ; Lee JH; Yoon JH
BMC Cancer; 2019 May; 19(1):523. PubMed ID: 31151419
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant ICIs Plus Targeted Therapies Reduce HCC Recurrence after Hepatectomy in Patients with High Risk of Recurrence.
Yang J; Jiang S; Chen Y; Zhang J; Deng Y
Curr Oncol; 2023 Jan; 30(2):1708-1719. PubMed ID: 36826093
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection.
Chen LT; Chen MF; Li LA; Lee PH; Jeng LB; Lin DY; Wu CC; Mok KT; Chen CL; Lee WC; Chau GY; Chen YS; Lui WY; Hsiao CF; Whang-Peng J; Chen PJ;
Ann Surg; 2012 Jan; 255(1):8-17. PubMed ID: 22104564
[TBL] [Abstract][Full Text] [Related]
7. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
Ke Q; Xin F; Fang H; Zeng Y; Wang L; Liu J
Front Immunol; 2022; 13():913464. PubMed ID: 35677059
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of postoperative adjuvant therapy with atezolizumab and bevacizumab after radical resection of hepatocellular carcinoma.
Li ZX; Zhang QF; Huang JM; Huang SJ; Liang HB; Chen H; Lai ZH; Li QY; Qian JP; Wang K; Zhou J
Clin Res Hepatol Gastroenterol; 2023 Aug; 47(7):102165. PubMed ID: 37330005
[TBL] [Abstract][Full Text] [Related]
9. Postoperative adjuvant tyrosine kinase inhibitors combined with anti-PD-1 antibodies improves surgical outcomes for hepatocellular carcinoma with high-risk recurrent factors.
Li J; Wang WQ; Zhu RH; Lv X; Wang JL; Liang BY; Zhang EL; Huang ZY
Front Immunol; 2023; 14():1202039. PubMed ID: 37359534
[TBL] [Abstract][Full Text] [Related]
10. Association of perioperative use of statins, metformin, and aspirin with recurrence after curative liver resection in patients with hepatocellular carcinoma: A propensity score matching analysis.
Khajeh E; Aminizadeh E; Moghadam AD; Ramouz A; Klotz R; Golriz M; Merle U; Springfeld C; Chang DH; Longerich T; Büchler MW; Mehrabi A
Cancer Med; 2023 Oct; 12(19):19548-19559. PubMed ID: 37737550
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence.
Lei J; Zhong J; Hao J; Liu Z; Zhang P; Wu L; Yan L; Zhu J; Zeng Y; Li B; Wen T; Wang W
Oncotarget; 2016 Jul; 7(27):42598-42607. PubMed ID: 26981887
[TBL] [Abstract][Full Text] [Related]
12. Perioperative blood transfusion does not influence recurrence-free and overall survivals after curative resection for hepatocellular carcinoma: A Propensity Score Matching Analysis.
Yang T; Lu JH; Lau WY; Zhang TY; Zhang H; Shen YN; Alshebeeb K; Wu MC; Schwartz M; Shen F
J Hepatol; 2016 Mar; 64(3):583-93. PubMed ID: 26596543
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma.
Jang YJ; Kim EJ; Kim HD; Kim KP; Ryu MH; Park SR; Choi WM; Lee D; Choi J; Shim JH; Kim KM; Lim YS; Lee HC; Ryoo BY; Yoo C
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7547-7555. PubMed ID: 36971796
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.
Wang R; Lin N; Mao B; Wu Q
J Cancer Res Clin Oncol; 2022 May; 148(5):1195-1210. PubMed ID: 34297207
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial.
Xia Y; Qiu Y; Li J; Shi L; Wang K; Xi T; Shen F; Yan Z; Wu M
Ann Surg Oncol; 2010 Dec; 17(12):3137-44. PubMed ID: 20602260
[TBL] [Abstract][Full Text] [Related]
16. Association of Adjuvant Radiation Therapy With Long-Term Overall and Recurrence-Free Survival After Hepatectomy for Hepatocellular Carcinoma: A Multicenter Propensity-Matched Study.
Gou XX; Shi HY; Li C; Chen ZL; Ouyang W; Sun LY; Diao YK; Wang MD; Yao LQ; Gu LH; Pawlik TM; Lau WY; Shen F; Xue J; Yang T
Int J Radiat Oncol Biol Phys; 2022 Oct; 114(2):238-249. PubMed ID: 35643251
[TBL] [Abstract][Full Text] [Related]
17. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
18. Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma.
Yang SY; Wang CC; Chen KD; Liu YW; Lin CC; Chuang CH; Tsai YC; Yao CC; Yen YH; Hsiao CC; Hu TH; Tsai MC
BMC Cancer; 2021 Jan; 21(1):70. PubMed ID: 33446127
[TBL] [Abstract][Full Text] [Related]
19. Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy.
Qiao W; Wang Q; Hu C; Zhang Y; Li J; Sun Y; Yuan C; Wang W; Liu B; Zhang Y
Front Immunol; 2022; 13():1019772. PubMed ID: 36389724
[TBL] [Abstract][Full Text] [Related]
20. Can adjuvant immune checkpoint inhibitors improve the long-term outcomes of hepatocellular carcinoma with high-risk recurrent factors after liver resection? A meta-analysis and systematic review.
Hu L; Kong Y; Qiao Y; Wang A
Front Oncol; 2024; 14():1374262. PubMed ID: 38854716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
